1. Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis
   Paula Adriana Rozenfeld et al, 2020, Molecular Genetics and Metabolism CrossRef
2. EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas
   Camille Lachat et al, 2020, Cancers CrossRef
3. The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations
   Valentina Citro et al, 2016, International Journal of Molecular Sciences CrossRef
4. Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy
   Fabian Braun et al, 2023, Journal of Clinical Investigation CrossRef
5. Icariin inhibits epithelial mesenchymal transition of renal tubular epithelial cells via regulating the miR-122-5p/FOXP2 axis in diabetic nephropathy rats
   Li Zang et al, 2022, Journal of Pharmacological Sciences CrossRef
6. α‐Galactosidase A‐deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease
   James J. Miller et al, 2019, The FASEB Journal CrossRef
7. Therapeutic effects of icariin and icariside II on diabetes mellitus and its complications
   Wei Jiang et al, 2023, Critical Reviews in Food Science and Nutrition CrossRef
8. The role of tubular cells in the pathogenesis of Fabry nephropathy
   Paula Rozenfeld et al, 2024, Frontiers in Cardiovascular Medicine CrossRef
9. Signatures of Altered Gene Expression in Dorsal Root Ganglia of a Fabry Disease Mouse Model
   Kai K. Kummer et al, 2018, Frontiers in Molecular Neuroscience CrossRef
10. ADAMTS6: Emerging roles in cardiovascular, musculoskeletal and cancer biology
    Timothy J. Mead, 2022, Frontiers in Molecular Biosciences CrossRef
11. Lyso-glycosphingolipid abnormalities in different murine models of lysosomal storage disorders
    Maria J. Ferraz et al, 2016, Molecular Genetics and Metabolism CrossRef